Acadia Pharmaceuticals, Inc.

Favorable results presented from phase Ib/IIa trial of ACP-103

Published in Telemedicine Law Weekly, July 31st, 2004

Acadia Pharmaceuticals, Inc., (ACAD) presented, at the CNS Diseases Congress held in Philadelphia, results of a phase Ib/IIa clinical trial of ACP-103 in patients with Parkinson disease and results from a human brain receptor occupancy study of ACP-103 performed using position emission tomography (PET).

Results of these studies demonstrated that ACP-103, Acadia's proprietary 5-HT2A inverse agonist, was safe and well tolerated in Parkinson disease patients at drug plasma levels many fold higher than those required for maximal brain occupancy of the 5-HT2A receptors, suggesting a large therapeutic index.

ACP-103 was discovered by scientists at Acadia...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly

Source: Telemedicine Law Weekly (2004-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry